

# A Randomized Controlled Trial of Sublingual Immunotherapy for Japanese Cedar Pollinosis

Shigetoshi Horiguchi<sup>a</sup> Yoshitaka Okamoto<sup>a</sup> Syuji Yonekura<sup>a</sup> Toru Okawa<sup>a</sup>  
Heizaburou Yamamoto<sup>a</sup> Naoki Kunii<sup>a</sup> Daiju Sakurai<sup>a</sup> Takashi Fujimura<sup>a</sup>  
Kazuyoshi Nakazawa<sup>b</sup> Hiroshi Yasueda<sup>c</sup>

<sup>a</sup>Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University  
and <sup>b</sup>Department of Pharmacy, Chiba University Hospital, Chiba, and <sup>c</sup>Clinical Research Center,  
National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan

## Key Words

Specific Immunotherapy • Allergic rhinitis • Clinical trial •  
Th2 • T cell clone

## Abstract

**Background:** Japanese cedar pollen represents an important and unique allergen. Sublingual immunotherapy (SLIT) has been suggested to be a highly effective route of desensitization against a variety of allergens. However, little information is available about its use in cedar pollen allergy.

**Methods:** A blinded randomized, placebo-controlled trial employing SLIT for cedar pollinosis was conducted over a period of 6 months. Sixty-seven subjects were enrolled and the symptom scores during the pollen season were evaluated by a symptom diary, measurement of cedar-specific IgE and IgG4, and determination of Cry j-specific Th2 clones before SLIT and before and after the pollen season. **Results:** No major adverse effects were observed in either group. The serum-specific IgG4 activity increased significantly after SLIT in the active group. The active group also exhibited significantly lower symptom scores compared to the placebo. The specific Th2 clone sizes were not significantly different between the groups before the pollen season. However, an increase in the clone size was observed after the pollen sea-

son in the placebo group, but not in the active group. **Conclusion:** Use of SLIT for Japanese cedar pollinosis was found to be safe and associated with an increase in cedar-specific IgG4 levels. Such therapy inhibited the increase in Cry j-specific Th2 clone size induced by pollen exposure. Finally, use of SLIT resulted in significant improvement of the clinical symptoms of cedar pollinosis in this patient population. These observations suggest that SLIT may offer another safe approach to the management of cedar pollinosis.

Copyright © 2007 S. Karger AG, Basel

## Introduction

In recent years, many countries have experienced an increase in the prevalence of allergic rhinitis as well as other allergic disorders [1, 2]. The most important pollen allergens in Japan are tree pollens, such as the Japanese cedar and Japanese cypress [3, 4]. With the exception of the Hokkaido and Okinawa regions, the Japanese cedar is widely distributed and occupies more than 18% of Japan's land surface area. The Japanese cypress is distributed predominantly to the west of the Kanto region. However, the planting of Japanese cedar trees is increasing. Cedar and cypress pollens share a common antigen

## KARGER

Fax +41 61 306 12 34  
E-Mail karger@karger.ch  
www.karger.com

© 2007 S. Karger AG, Basel  
1018–2438/08/1461–0076\$24.50/0

Accessible online at:  
www.karger.com/iaa

Correspondence to: Dr. Yoshitaka Okamoto  
Department of Otolaryngology, Head and Neck Surgery  
Graduate School of Medicine, Chiba University  
1-8-1 Inohana, Chuo-ku, Chiba 260-8670 (Japan)  
Tel. +81 43 226 2137, Fax +81 43 227 3442, E-Mail yokamoto@faculty.chiba-u.jp

and more than 70% of patients who are allergic to cedar pollen also develop cypress pollinosis [5, 6]. Around the Tokyo region, the cedar pollen season usually starts in the middle of February and is followed by the cypress pollen season which lasts until the beginning of May. Consequently, many patients with cedar pollinosis suffer from heavy pollen exposure for almost 12 weeks. In addition, Japanese cedar and cypress pollen can travel more than 100 km from the source, thereby raining down large amounts of pollen on other large cities. This situation is considerably different from that experienced in other countries where the most common allergens are grass pollens and ragweed, which generally travel distances of several hundred meters, and the pollen season lasts for less than 6 weeks [7]; however, it is similar to Northern European countries and North America where birch and other tree pollens are the major contributors.

Subcutaneous allergen-specific immunotherapy (SCIT) has been evaluated and shown to be an effective approach to change the course of allergic rhinitis [8–13], including Japanese cedar pollinosis [14]. However, an alternative method of administration is still required because the SCIT approach has been associated with the risk, albeit very low, of anaphylactic shock [15] and the inconvenience of frequent visits to the physician's office.

A recent review of randomized controlled studies of sublingual immunotherapy (SLIT) conducted outside Japan has strongly suggested its efficacy against a variety of allergens [16–21]. SLIT could be an attractive approach for Japanese cedar pollinosis if efficacy, safety, mechanisms and effective biomarkers can be clearly established.

The present placebo-controlled randomized studies were designed to determine the effects of SLIT on Japanese cedar pollinosis employing recombinant hybrid peptides consisting of 7 HLA class 2 restricted T cell epitopes of Cry J, the major allergen of Japanese cedar pollen [22].

## Methods

### Subjects

The study population consisted of 67 patients (33 males and 34 females), ranging in age from 20 to 37 years, who were otherwise healthy, but had a clinical history of Japanese cedar pollinosis for at least the last 3 consecutive cedar pollen seasons. The subjects lived in and around the city of Chiba, where a similar amount of pollen spread would be expected. The diagnosis of cedar pollinosis was based on clinical history, positive allergen-specific skin tests (wheal diameter  $\geq 10$  mm) to a standardized cedar pollen extract (Torii Pharmaceutical Co. Ltd., Tokyo, Japan) and serum

cedar pollen-specific IgE levels of  $\geq$  score 2 by the CAP radioallergosorbent test (CAP-RAST; SRL, Tokyo, Japan). The exclusion criteria included a history of severe asthma, use of antiallergic drugs within 4 weeks and a prior history of any allergen-specific immunotherapy, including therapy for cedar pollen. Pregnant women or those at risk of pregnancy were also excluded. The study was conducted at the Chiba University Hospital and the protocol was approved by the Ethics Committee of Chiba University; written informed consent was obtained from each of the patients prior to participation in this study.

### Japanese Cedar Pollen Extracts

Standardized Japanese cedar pollen extracts (Torii Pharmaceutical Co. Ltd.) were used [23]. The extract [1,000 Japanese Allergy Units (JAU)/ml] contained 1.5  $\mu$ g of Cry j 1, which is the major allergen of Japanese cedar pollen. The amount of Cry j 1 was quantitated by an enzyme-linked immunosorbent assay, as reported previously [24].

### Study Protocol

The study was placebo controlled and single blinded. The enrolled subjects were randomly divided into 2 groups with a ratio of 2:1 according to the table of random numbers by the Department of Pharmacy at the Chiba University Hospital. A controller who was not directly involved in this study was responsible for group allocation. The patients were divided randomly into the active (treatment) and placebo groups. A group allocation number was given to each patient. To prevent the leakage of information, this number was closely guarded jointly by the controller and a member of the ethical committee who was also not directly involved in the study, until accessed with the key after the completion of the study. The active group consisted of 43 patients who received the pollen extract and the placebo group consisted of 24 patients who received the placebo (inactive) for sublingual administration by the spit method (table 1). The sample size was determined based on previous similar studies [25]. The induction/buildup phase was 1 month, with the administration of an increasing daily number of the extract drops at 3 concentrations. The patients received 1 ml of 1,000 JAU extract or placebo once weekly as shown in table 2. Although the safety of the daily administration of SLIT has been reported recently, the weekly administration was chosen in this study in order to further reduce the possibility of any serious adverse events. No study of SLIT for Japanese cedar pollinosis has been reported to date. However, the development of asthma attacks by exposure to pollen has been observed in some patients [14]. The maintenance dose of the antigen in the present SLIT studies was about 100 times higher than that routinely used in SCIT. Administration was started at the beginning of October 2005 and ended at the end of April 2006. The patients carefully completed a pollen diary regarding their nasal symptoms and the usage of rescue drugs (such as antihistamines). Data were collected and analyzed at the Department of Clinical Testing of the Chiba University Hospital.

The nasal symptoms were evaluated on a scale from 0 to 4 in accordance with the *Practical Guidelines for the Treatment of Allergic Rhinitis, Japan* [26], as follows: 0 = no sensation; 1 = mild; 2 = moderate; 3 = severe; 4 = extremely severe. Daily episodes of sneezing and nose blowing were rated 0–4, as follows: 0 = none; 1 = 1–5 episodes; 2 = 6–10 episodes; 3 = 11–20 episodes; 4 = more than 20 episodes. The medications were also recorded according

to drug characteristics and duration of usage, according to the guidelines as follows: antihistamines, mast cell stabilizers and vasoconstrictors were listed as 1, topical ocular or nasal steroids as 2.

#### Immunoglobulin Assay

Serum Cry j 1-specific IgG4 antibodies were measured using microtiter plates coated with 100 ng/well of Cry j 1 which was purified as reported previously [27]. Allergen-coated wells with serum samples (diluted 1:50) were incubated for 2 h at 37°C, and then washed with PBS. The plates were incubated with 100 µl of biotinylated monoclonal anti-IgG4 antibody (BD Pharmingen; 500 ng/ml) for 1 h at 37°C, and then overnight at 4°C. After washing, the plates were incubated with 100 µl of streptavidin-γ-D-galactosidase conjugate (Roche Diagnostics) at 1:2,000 dilution for 1 h at 37°C, and washed. Finally, 100 µl of 5 mM o-nitrophenyl-β-D-galactopyranoside was added to the wells and incubated for 1 h at 37°C. After the enzyme reaction was stopped with 100 µl of 0.1 M Na<sub>2</sub>CO<sub>3</sub>, the absorbance at 415 nm was read using a microplate reader.

The specific IgG4 antibody levels were calculated from control curves with serial dilutions of a reference serum pool, which was prepared from 5 sera with high levels of Cry j 1-specific IgG antibody. The IgG4 antibody levels in the reference pool serum were arbitrarily assigned to be 100 U/ml.

#### Analysis of Th Cytokines and Cell Clones

Peripheral blood mononuclear cells (PBMCs) were obtained by the Ficoll-Hypaque method and stored at -80°C until analysis, using a cell banker (Nippon Zenyaku Kogyo Co. Ltd., Fukushima, Japan).

Th1/Th2 cytokine profiles were analyzed using FACS analysis. PBMCs ( $5 \times 10^5$ ) were stimulated with PMA and ionomycin for 4 h in the presence of 2 µM monensin, which inhibited the secretion of protein produced de novo. The cells were stained with anti-CD4 antibody for 15 min on ice. After washing with PBS, the cells were fixed with 4% paraformaldehyde for 10 min at room temperature and permeabilized with 0.5% Triton X-100 for 10 min on ice. After blocking with 3% bovine serum albumin for 10 min, the cells were incubated on ice for 30 min with anti-IFN-γ labeled with fluorescein isothiocyanate and anti-IL-4 labeled with phycoerythrin. A flow-cytometric analysis was performed on FACS Calibur (Becton Dickinson, Irvine, Calif., USA). The antibodies for FACS analysis were purchased from BD Bioscience (San Diego, Calif., USA).

The Cry j-specific Th2 clone sizes were determined by an ELISPOT assay using the recombinant hybrid peptide. The hybrid peptide comprised the 7 CD4 T cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens [22]. Almost the entire patient population with Japanese cedar pollinosis respond to this hybrid peptide and the responses are comparable to the individual responses to Cry j 1 and Cry j 2 [22]. The monoclonal antibodies used in the ELISPOT analysis were obtained from Mabtech (Stockholm, Sweden). The anti-human IL-4 or IL-5 monoclonal antibodies were diluted to a concentration of 15 µg/ml in sterile, filtered (0.45 µm) PBS (pH 7.2), and 100 µl per well were added onto nitro-cellulose plates (Millititer; Millipore Corp., Bedford, Mass., USA). The plates were incubated overnight at 4°C and the unbound antibodies were washed with filtered PBS thereafter. After the last wash, PBS was sucked through the membrane

**Table 1.** Baseline characteristics of the patients

|                                                                          | Treatment group<br>(n = 43) | Placebo group<br>(n = 24) |
|--------------------------------------------------------------------------|-----------------------------|---------------------------|
| Mean age, years <sup>1</sup>                                             | 26.8 ± 5.4                  | 26.4 ± 5.9                |
| Female sex                                                               | 21 (48.8)                   | 13 (54.2)                 |
| Mean duration of cedar pollinosis, years                                 | 8.7                         | 9.1                       |
| Type of allergic rhinitis                                                |                             |                           |
| Cedar pollinosis with perennial                                          | 7 (16.3)                    | 3 (17.5)                  |
| Cedar pollinosis with other pollinosis                                   | 5 (11.6)                    | 4 (16.7)                  |
| Cedar pollinosis only                                                    | 31 (70.5)                   | 17 (70.8)                 |
| Additional allergic history                                              |                             |                           |
| History of asthma symptoms                                               | 2 (4.6)                     | 0                         |
| Current asthma symptoms                                                  | 0                           | 0                         |
| History of allergic conjunctivitis                                       | 40 (93.0)                   | 19 (75.0)                 |
| Cedar pollen RAST score <sup>1</sup>                                     | 4.18 ± 1.01                 | 4.14 ± 0.92               |
| Peak of daily total nasal symptoms score in the last cedar pollen season | 4.8                         | 4.5                       |

Figures in parentheses are percentages.

<sup>1</sup> Data are means ± SD.

**Table 2.** Dose and dosing frequency

|       | Week 1<br>20 JAU | Week 2<br>200 JAU | Week 3<br>2,000 JAU | Week 4<br>2,000 JAU |
|-------|------------------|-------------------|---------------------|---------------------|
| Day 1 | 0.2 ml           | 0.2 ml            | 0.2 ml              | 1.0 ml              |
| Day 2 | 0.4 ml           | 0.4 ml            | 0.4 ml              |                     |
| Day 3 | 0.6 ml           | 0.6 ml            | 0.6 ml              |                     |
| Day 4 | 0.8 ml           | 0.8 ml            | 0.8 ml              |                     |
| Day 5 | 1.0 ml           | 1.0 ml            | 1.0 ml              |                     |
| Day 6 |                  |                   |                     |                     |
| Day 7 |                  |                   |                     |                     |

The induction phase with an increasing number of extract drops over 5 days a week at 3 concentrations for 3 weeks and the maintenance phase (week 4) with 1 ml of 1,000 JAU extracts once weekly are shown.

under vacuum (Millipore). One hundred microliters of AIM-V medium with or without 20 µM hybrid peptide was added to  $5 \times 10^5$  cells per well, and the plates were incubated for 10 h at 37°C. All assays were done in duplicate. The cells were subsequently washed before adding 100 µl of the biotinylated monoclonal antibodies (1 µg/ml), and incubated for 2 h at room temperature.

The plates were washed and incubated for 90 min at room temperature with 100 µl of streptavidin alkaline phosphatase (Mabtech) at a dilution of 1:1,000. The unbound conjugate was removed by another series of rinsing before 100 µl of BCIP/NBT substrate solution (Bio-Rad, Richmond, Calif., USA) was added and the plates were incubated at room temperature until dark

**Fig. 1.** Daily combined Japanese cedar and cypress pollen counts in 2006 in Chiba measured by the Durham pollen sampler and symptom-medication score (mean values) of patients during the pollen season.





**Table 3.** Study participation



spots emerged (1 h). The color development was stopped by repeated rinsing with tap water. After drying, the spots were captured photoelectrically and counted by a computed analysis to avoid any visual bias, using an auto counter (ImmunoScan; CTL, Cleveland, Ohio, USA).

#### Statistical Analysis

After completion of the study, the clinical and laboratory data were analyzed by a biostatistician who was not involved in carrying out the clinical trial. After completing the analysis, the allocation identification numbers for the active and placebo groups were accessed with a key. The Mann-Whitney U test was performed to compare symptom scores as well as symptom-medication scores between placebo and active groups. The Wilcoxon

signed rank test was used for paired comparisons of the Cry j 1 specific IgG4 levels before and after SLIT. All statistical analysis was performed using the GraphPad Prism software, version 4.

During the statistical calculations in the present studies, the  $\beta$  error was defined as 0.2, power was 80% and the  $\alpha$  error was defined as 0.05. Values of  $p < 0.05$  were considered statistically significant.

## Results

Four patients were withdrawn from the study for personal reasons, but not due to any adverse effects. All other subjects exhibited full compliance with the study protocol. As a result, 63 patients (41 patients from the active group and 22 patients from the placebo group) were analyzed further for effectiveness of SLIT (table 3).

#### Adverse Effects

Fifteen adverse effects were reported during the treatment. Of these, 13 subjects were in the active treatment group and 2 in the placebo group. Two patients in the active group complained of mild urticaria of the face or breast. The remaining subjects exhibited mild oral pruritus or oral pain (Common Terminology Criteria for Adverse Event grade 1). All adverse effects were transient and resolved spontaneously. No intervention was necessary.




**Fig. 2.** Average symptom scores of sneezing, nasal secretion, nasal obstruction and symptom-medication score during the high pollen season, from 20 February to 27 March 2006. The average score of the active group was significantly lower than that of the placebo group.




**Fig. 3.** Levels of serum Cry j 1-specific IgG4 before/after pollen dispersal. Specific IgG4 significantly increased in the active group but not in the placebo group and a significant difference was observed between the groups ( $p < 0.05$ ).

#### Pollen Counts

In 2006, the Japanese cedar pollen season started in the middle of February and was followed by cypress pollen, which continued until the end of April. The duration of the pollen season extended from 20 February to 27 March. The combined annual amount of cedar and cypress pollen was  $1,154/\text{cm}^2$  according to the Durham pollen sampler in Chiba.

#### Symptoms

The nasal symptoms and medication scores during the pollen season are shown in figures 1 and 2. The temporal profiles of nasal symptoms and medication scores were in general similar in the active and placebo groups and reflected the pollen counts in the community. However, the scores were lower in the active (treatment) group, especially during the peak of the pollen season as shown in figure 1.

The symptom scores for sneezing, nasal secretion volume, degree of nasal obstruction and medication scores were significantly higher in the placebo group compared to the active (treatment) group ( $p < 0.01$ ) during the peak of the pollen season as shown in figure 2.




**Fig. 4.** Relative change of Cry j-specific IL-4 and IL-5 clone sizes in May, after the pollen season, compared with those in January before the season.

#### Serum Immunoglobulin

There were no significant differences in the 2 study groups for the Japanese cedar pollen-specific IgE and IgG4 levels in the serum samples collected in October, just before SLIT was initiated. On the other hand, after the initiation of immunotherapy, Cry j-specific IgG4 levels exhibited a significant increase in the active group in January before the pollen season. Significantly higher levels of specific IgG4 were observed in the active group for at least 4 months after the initiation of the immunotherapy as shown in figure 3. No significant effects of immunotherapy were detected for the levels of specific IgE (data not shown). No changes in the specific IgE levels were observed relative to the cedar pollen dispersion between January and May. The levels of specific IgG4 also did not exhibit any change after pollen exposure in both the active and placebo groups (fig. 4) and the levels did not correlate with the nasal symptom scores (data not shown).

#### Th1/Th2 Cytokine Profiles

The number of Th1/Th2 cells in the peripheral blood CD4 T cells did not change significantly and no significant difference was observed between the 2 groups during the study period (data not shown).

#### Cry j-Specific Th2 Clone Sizes

The number of Cry j-specific IL-4 and IL-5 spots showed a strong correlation. Although the number of spots was similar between the active and placebo groups

before the pollen season, a significant increase in IL-4 spots was observed only in the placebo group after the pollen season. The increase in IL-4 clone size during the pollen season in the active and placebo groups was  $1.71 \pm 0.71$  and  $0.70 \pm 0.52$  (mean  $\pm$  SD), respectively ( $p < 0.0001$ ). On the other hand, the increase in IL-5 clone size between the active and placebo groups was not significant, the power ( $1 - \beta$  error) was 0.58 ( $p = 0.09$ ) as shown in figure 4.

#### Discussion

Although the use of SCIT has been found to be safe for immunotherapy for a variety of pollen allergies, the practical inconvenience associated with its use prompted this study to explore alternative routes of administration. A recent review of randomized controlled studies of SLIT has suggested both its efficacy and safety [16–21]. Although SLIT for Japanese cedar pollinosis is an attractive alternative route, no randomized controlled studies have been carried out to date. The observations of particular importance reported here have shown that the use of SLIT significantly increased the levels of pollen-specific IgG and downregulated the size of pollen-specific Th2 lymphocyte subset clones.

In order to avoid adverse effects, such as local pain and swelling associated with injection and possible anaphylactic reactions, a dose of 40 JAU/month as a maintenance dose has generally been utilized in SCIT for Japanese pol-

linosis. In this study 1,000 JAU/week (4,000 JAU/month) was used as a maintenance dose in SLIT, which was 100 times more than that used in SCIT. The choice for such a dose was somewhat arbitrary and the optimal dose required for effective and safe use of SLIT remains to be determined.

The combined Japanese cedar and cypress pollen counts generally exceed 3,000/cm<sup>2</sup>, as measured by the Durham pollen sampler in Chiba and Tokyo. However, in 2006 the pollen counts were 1,154/cm<sup>2</sup>, which was one third of the average for the last 5 years. In Japan, the pollen counts and the counts/cm<sup>2</sup> are usually measured by the Durham samplers, which utilize a gravimetric method that is different from the Burkard sampler, a volumetric method that is widely used in European countries. Direct comparison of the counts by the 2 methods can be difficult, because the ratio between the 2 methods depends on the local meteorological conditions and the types of pollen. When these methods were compared in 2005, the counts obtained by the Burkard sampler were about 12 times higher than those obtained by the Durham sampler [28].

During SLIT, no adverse effects greater than Common Terminology Criteria for Adverse Event grade 3 were observed. Three months after SLIT, serum Cry j 1-specific IgG4 was elevated in the active group. However, the specific IgE levels were not significantly different between the groups.

Several previous studies employing SLIT have observed an increase in allergen-specific IgG4 levels and specific IgG4/IgE ratios in the serum [29, 30]. However, the precise role of increased IgG4 in the effectiveness and outcome of such immunotherapy remains to be determined. Lima et al. [31] reported that the IgG levels correlated with the clinical efficacy as a blocking antibody, but other studies have failed to demonstrate such a correlation [32]. The increased levels of Cry j 1-specific IgG4 antibody in this study indicate that SLIT can induce specific antibody responses. However, the role of IgG4 antibody in the mechanisms of clinical effectiveness remains to be defined. No relationship between the IgG4 responses and the clinical efficacy was observed in this study.

In the present studies, the use of SLIT was associated with milder clinical symptoms and lower medication scores during the pollen season and a significant reduction in each symptom was observed. As pointed out earlier, the doses in this SLIT study were much higher than those generally used in SCIT. However, in SLIT with other allergens, the clinical efficacy has been shown to be allergen dose dependant [33]. Although the swallow-SLIT

method is currently widely used, we selected the spit-SLIT method to further reduce the possibility of adverse effects, since no SLIT trials with Japanese cedar pollinosis have been carried out to date. Further studies will be needed to assess the dose responses, temporal intervals and vehicles of administration to obtain optimal effectiveness with SLIT.

Cedar pollen-specific IgE and IgG4 did not increase significantly with pollen exposure, which might be explained in part by the relatively small amount of pollen dispersal observed during these studies.

The total number of Th2 cells in the peripheral blood did not increase during the pollen season and Th1/Th2 cytokine profiles did not change throughout the study in either group. However, the profiles of the allergen-specific Th cells were quite different. The patients with cedar pollinosis are thought to have cedar pollen-specific memory Th cell clones and the treatment is aimed at diminishing the size of Th2 clones. Since the Th cell response is restricted in MHC class 2, it is necessary to use a class 2 restrictive T cell epitope to measure the reaction of T cell clones in response to the allergen. Japanese cedar-specific IL-4 and IL-5 producing memory T cell in the peripheral blood were examined by an ELISPOT assay using Japanese cedar pollen-specific peptides. Although the number of cedar peptide IL-4 and IL-5 T cells was low, all patients exhibited specific spots, ranging from 5 to 100 spots/10<sup>5</sup> PBMCs. The number of cedar pollen-specific Th2 cells did not correlate with the cedar pollen-specific serum IgE nor IgG4 levels. This may be related to the possibility that IgE and IgG4 synthesis is controlled by many other factors, including Th1 cells and memory B cells.

The size of the cedar pollen-specific Th2 cell clones was not different between the active and the placebo groups before the pollen season. Interestingly, these Cry j-specific Th2 clone sizes were increased about 1.7-fold during the cedar pollen season by pollen exposure in the placebo group. However, this increase was not observed in the active group and SLIT suppressed the increase in specific Th2 clone sizes. The change in the clone size did not correlate with the levels of allergen-specific IgG4 antibody.

Several recent studies have explored the significance of regulatory T cells in allergic and autoimmune disorders [34–37]. The suppression of allergen-specific Th2 clones observed in this study may be a reflection of such regulatory T cells, although the precise contribution of different T cell subsets remains to be examined.

In summary, this study has demonstrated that SLIT for Japanese cedar pollinosis was safe and is associated with increased cedar pollen-specific IgG4. Such therapy also inhibited the increase in specific Th2 lymphocyte clone sizes induced by the exposure to cedar pollen. It is also suggested that the use of SLIT appears to be an acceptable alternative to SCIT for Japanese cedar pollinosis.

## Acknowledgements

This work was supported by a grant from the Ministry of Health, Labor and Welfare. The authors thank Prof. Pearay L. Ogra for helpful comments.

## References

- Bousquet J, van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization: Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108: s147–s334.
- Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. *Lancet* 1998;351:1225–1232.
- Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. *Ann Allergy Asthma Immunol* 2003;91:288–296.
- Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A: Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. *Int Arch Allergy Immunol* 2005; 136:365–371.
- Ito Y, Takahashi Y, Fujita T, Fukuyama S: Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. *Auris Nasus Larynx* 1997;24:163–170.
- Ito H, Nishimura J, Suzuki M, Mamiya S, Sato K, Takagi I, Baba S: Specific IgE to Japanese cypress (*Chamaecyparis obtusa*) in patients with nasal allergy. *Ann Allergy Asthma Immunol* 1995;74:299–303.
- Katellaris CH, Burke TV, Byth K: Spatial variability in the pollen count in Sydney, Australia: can one sampling site accurately reflect the pollen count for a region? *Ann Allergy Asthma Immunol* 2004;93:131–136.
- Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D; Immune Tolerance Network Group: Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. *N Engl J Med* 2006;355:1445–1455.
- Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. *Allergy* 2006;61: 1177–1183.
- Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2006;118:434–440.
- Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. *BMJ* 1991;302:265–269.
- Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR: Grass pollen immunotherapy: efficacy and safety during a 4-year follow up study. *Allergy* 1995;50:405–413.
- Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M: A double-blind placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. *Allergy* 1996;51:489–500.
- Okuda M: A long-term follow-up study after discontinuation of immunotherapy for Japanese cedar pollinosis. *Arerugi* 2006;55:655–661.
- Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC: Systemic reactions and fatalities associated with allergen immunotherapy. *Ann Allergy Asthma Immunol* 2001;87(suppl 1):47–55.
- Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS: Sublingual immunotherapy: a comprehensive review. *J Allergy Clin Immunol* 2006;117:1021–1035.
- Burastero SE: Sublingual immunotherapy for allergic rhinitis: an update. *Curr Opin Otolaryngol Head Neck Surg* 2006;14:197–201.
- Passalacqua G, Lombardi C, Guerra L, Compalati E, Fumagalli F, Canonica GW: Sublingual immunotherapy: no more doubts. *Allerg Immunol (Paris)* 2005;37:314–320.
- Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. *Allergy* 2005;60:4–12.
- Bousquet J, Demoly P: Specific immunotherapy – an optimistic future. *Allergy* 2006; 61:1155–1158.
- Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ: Safety and tolerability of grass pollen tablets in sublingual immunotherapy: a phase-1 study. *Allergy* 2006;61:1173–1176.
- Hirahara K, Tatsuta T, Takatori T, Ohtsuki M, Kirinaka H, Kawaguchi J, Serizawa N, Taniguchi Y, Saito S, Sakaguchi M, Inouye S, Shiraishi A: Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. *J Allergy Clin Immunol* 2001;108:94–100.
- Ohkubo K, Takizawa R, Gotoh M, Okuda M: Experience of specific immunotherapy with standardized Japanese cedar pollen extract. *Arerugi* 2001;50:520–527.
- Yasueda H, Akiyama K, Maeda Y, Hayakawa T, Kaneko F, Hasegawa M, Shida T: An enzyme-linked immunosorbent assay (ELISA) for the quantitation of sugi pollen and *Der-matophagoides* mite allergens and its application for standardization of allergen extracts. *Arerugi* 1991;40:1218–1225.
- Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. *Allergy* 2005;60:4–12.
- Okuda M: Grading the severity of allergic rhinitis for treatment strategy and drug study purposes. *Curr Allergy Asthma Rep* 2001;1:235–241.
- Yasueda H, Yui Y, Shimizu T, Shida T: Isolation and partial characterization of the major allergen from Japanese cedar (*Cryptomeria japonica*) pollen. *J Allergy Clin Immunol* 1983;71:77–86.
- Delaunay J, Sasajima H, Okamoto Y, Yokota M: Side-by-side comparison of automatic pollen counters for use in pollen information system. *Ann Allergy Asthma Immunol* 2007; 98:553–558.
- La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 1999;104:425–432.

- 30 Pajno GB, Morabito L, Barberio G: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. *Allergy* 2000;55:842–849.
- 31 Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. *Clin Exp Allergy* 2002;32:507–514.
- 32 Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. *Allergy* 2006;61:151–165.
- 33 Frati F, Incorvaia C, Marcucci F, Sensi L, Di Cara G, Puccinelli P, Dal Bo S: Dose dependence of efficacy but not of safety in sublingual immunotherapy. *Monaldi Arch Chest Dis* 2006;65:38–40.
- 34 Jutel M, Akdis M, Budak F, Aebischer-Casalta C, Wrzyszc M, Blaser K, Akdis CA: IL-10 and TGF- $\beta$  cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. *Eur J Immunol* 2003;33:1205–1214.
- 35 Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. *J Exp Med* 2004;199:1567–1575.
- 36 Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor- $\beta$ : the role of T regulatory cells. *Immunology* 2006;117:433–442.
- 37 Sun JB, Cuburu N, Blomquist M, Li BL, Czerkinsky C, Holmgren J: Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3<sup>+</sup> CD25<sup>+</sup> CD4<sup>+</sup> regulatory T cells and suppresses delayed-type hypersensitivity reactions. *Scand J Immunol* 2006;64:251–259.